28 January 2019 - - The US Food and Drug Administration has approved Tosymra (previously known as DFN-02) by the US Food and Drug Administration, Indian drugmaker Dr. Reddy's Laboratories Ltd. (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) and its US subsidiary, Promius Pharma, LLC said.

Tosymra is indicated for the acute treatment of migraine with or without aura in adults. Tosymra is the latest product to join the Promius Pharma acute migraine treatment portfolio.

The company is working toward commercialisation of this product.

Tosymra is a prescription medicine used to treat acute migraine headaches with or without aura in adults.

Intravail is a registered trademark of Neurelis, Inc. Intravail drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide drugs (up to 30,000 daltons in size) that can currently only be administered by injection.

Intravail can be utilized via the oral, buccal, dermal, and intranasal routes of drug administration.

Dr. Reddy's is an integrated pharmaceutical company that offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, and differentiated formulations.

Its major therapeutic areas of focus are gastroenterology, cardiology, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Its major markets include USA, India, Russia and CIS countries, and Europe.